Subject: Carrington To Make More Acemannan For AIDS
Date: Published: 4/14/92 (30 lines)
Source: Wall Street Journal. Copyright Dow Jones & Co. Inc.

    Financing Business:
    Carrington Laboratories Inc. 

    CARRINGTON LABORATORIES Inc. said it registered with the
 Securities and Exchange Commission to offer one million
 common shares and three million shares of a new research
 concern, Carntech Inc. Carrington, an Irving, Texas, maker of
 wound and skin-care products, said the Carntech offering will
 be of units, with each unit including one Carntech common
 share and one warrant to buy a share of Carrington.  The
 warrants will be exercisable between 1994 and 1997.
 Carrington said that Carntech is being created to speed
 development of products using acemannan, a derivative of the
 aloe vera plant, for the treatment of inflammatory bowel
 disease and cancer; proceeds from the Carntech offering will
 be used for that research.  Carrington said it will use
 proceeds from its stock offering for expansion of its
 acemannan-manufacturing capacity, expansion of its wound and
 skin care business, to further its research into the use of
 acemannan in treating AIDS and for general corporate
 purposes.  Currently, Carrington has about 6.7 million shares
 outstanding.

[This article is made available here by Dow Jones Co. for the
 personal and non-commercial use of callers to this bbs, in the
 hope that it will be of some help to those who are suffering
 from the disease and others who are seeking to help them.]